[A19-60] Cemiplimab - Benefit assessment according to §35a Social Code Book V
Last updated 04.11.2019
Project no.:
A19-60
Commission:
Commission awarded on 02.08.2019 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adults with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation
Added benefit neither proven for patients who have not yet received prior drug treatment nor for those whose cancer has progressed after prior drug therapy
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A23-37 | Cemiplimab (NSCLC, combination with platin-based chemotherapy) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A21-98 | Cemiplimab (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A21-97 | Cemiplimab (basal cell carcinoma) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-36 | Cemiplimab (cervical cancer) – Benefit assessment according to §35a Social Code Book V | Commission completed |